JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

Leukemia. 2016 Aug;30(8):1772-5. doi: 10.1038/leu.2016.45. Epub 2016 Feb 29.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Genotype
  • Humans
  • Janus Kinase 2 / genetics*
  • Male
  • Middle Aged
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / drug therapy
  • Myeloproliferative Disorders / genetics
  • Nitriles
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / genetics*
  • Proportional Hazards Models
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Splenomegaly / drug therapy*
  • Splenomegaly / etiology
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2